UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
11d
New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result in additive and synergistic effects on patient weight loss, and importantly ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback